HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.8%

Neg 0% Neu 89.8% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.